Description :
‘ Cancer biomarkers ’ are biomolecules that specifies the existence of cancer or cancerous cells in the body . These are generally molecules that are released due to the presence of a tumor or a particular indication in the body to the presence of cancer . These molecules are densely distributed in tissues , urine , serum , blood , and other body fluids . Their expression levels serve as the basis or indication of any abnormal process or a disease .
Check the DISCOUNT on this report @ http :// www . orbisresearch . com / contacts / discount / 216076 .
The market size of the global cancer biomarkers market was valued at $ 6,521 million in 2015 and is estimated to grow at a CAGR of 13 % over the forecast period to reach $ 15,737 million in 2022 . Market growth is attributed to the increasing incidences of cancers such as lung cancer , breast cancer , and prostate cancer among others coupled with growing importance of biological and targeted drug therapies and technological advancements in the field of cancer treatment . However , unregulated government laws and reimbursement policies ; as well as high cost of drug development and threat of failure are anticipated to have an adverse effect on the market growth . Nevertheless , advancement in cancer drugs research and significant unmet need in cancer diagnosis are estimated to overshadow these restraints .
The global cancer biomarkers market is segmented based on profiling technology , biomolecules , cancer type , application , and geography . By profiling technology , the market is segmented into omic technologies , imaging technologies , immunoassays and cytogenetics based tests . Based on biomolecules , the market is segmented into genetic biomarkers , protein biomarkers , and glycoprotein biomarkers . Amongst these , genetic biomarkers are widely used in the market owing to better diagnostic and therapeutic usage as compared to protein and glycoprotein biomarkers .
The various cancer types include breast cancer , lung cancer , prostate cancer , colorectal cancer , stomach cancer , and others . Amongst these , lung cancer is the major cancer type where biomarkers are being used for detection . Owing to high tobacco consumption and smoking , lung cancer has increased at an alarming rate . CEACAM-5 / CD66e , Cytokeratin 19 , EGF R / ErbB1 , Enolase 2 / Neuron-specific Enolase , Lactate Dehydrogenase A / LDHA , Lactate Dehydrogenase B / LDHB , Napsin A and PDGFRL are some of the major cancer biomarkers used for lung cancer detection .
Geographically , North America is the leading revenue generating region , due to high incidence rate of cancer , growth in awareness towards cancer and higher cancer biomarker testing . Asia-Pacific is growing at the fastest CAGR due to rise in awareness , increased disposable income , and affordability for advanced cancer treatments .
Companies have adopted collaboration and partnership as their key development strategies . Increase in focus on collaboration and partnership is mainly for the development of innovative technologies in the field of cancer biomarkers . In May 2016 , Roche received an
2